TAIKO PHARMACEUTICAL CO.,LTD.
TSE Prime
¥250.00
+0.40%
Delayed · cached 15 min
Price Chart
Price50-day avg200-day avg
How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.
✓Strengths
- Low debt: debt-to-equity of 0.44.
- Comfortable interest cover: operating profit covers interest about 91.8 times.
- Return on equity is moderate at 11.2%.
- Net profit margin is 14.4%.
- Current assets comfortably cover current liabilities (current ratio 3.36).
!Watch-points
- Return on capital employed is on the lower side at 4.7%.
- Sales growth has been slow over five years (about -13% a year).
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreDistress zone
1.62
In Altman’s study, scores in this range were associated with a higher incidence of financial distress.
Computed without the market-value term.
Piotroski F-ScoreModerate
4 / 4
The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.
Based on 4 of the 9 signals — the rest need data not available for this stock.
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Market Cap¥126億
Current Price¥ 250.00
High / Low¥ 317.00 / 246.00
Stock P/E18.248175
Book Value¥ 169.51
Dividend Yield5.49%
ROCE4.70%
ROE11.20%
Debt to Equity0.44
Current Ratio3.36
P/B Ratio0.47538006
EPS¥ 18.38
PAT Margin14.43%
ICR91.80
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity